Injectable Gel Composition for Localized Fat Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for reducing submental fat, such as deoxycholic acid injections, often result in significant inflammation, pain, and require long intervals between treatments due to the extensive inflammatory response.
Innovation Solution
Development of an injectable composition comprising deoxycholic acid or its salt, sodium deoxycholate, in a gel form, mixed with basic amino acids like L-lysine, L-arginine, and L-histidine, and/or organic acids like acetic acid, which forms a slow-releasing gel at the injection site, limiting cytolytic reaction to the immersed fat cells and reducing inflammation with the addition of anti-inflammatory drugs or local anesthetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deoxycholic acid solution is injected into fat tissue, then fat cells are destroyed effectively, but extensive inflammation reaction occurs throughout the entire fat tissue area
Solution Approach 1:
The patent segments the cytolytic action by forming a gel structure that localizes deoxycholic acid release to specific regions. The gel divides the treatment area into zones with different drug concentrations, confining the harsh cytolytic effect to the gel core while the periphery experiences milder effects, thus reducing overall inflammation.
Solution Approach 2:
The gel structure is formed beforehand before injection, pre-organizing the deoxycholic acid in a controlled release format. This preliminary gel formation ensures that the cytolytic compound is delivered in a spatially and temporally controlled manner, preventing premature widespread inflammation while maintaining effective fat destruction.
2Productivity
If deoxycholic acid is released quickly, then treatment time is short, but extensive inflammation and pain occur requiring long intervals between treatments
Solution Approach 1:
The gel provides periodic or sustained release of deoxycholic acid over time, transforming the instantaneous high-concentration burst into a controlled temporal profile. This periodic release maintains therapeutic effectiveness while avoiding the peak concentrations that trigger severe inflammation, thereby allowing shorter treatment intervals.
Solution Approach 2:
The patent changes the release rate parameter of deoxycholic acid by using gel formulation. The gel matrix controls the diffusion and degradation kinetics, transforming rapid release into sustained release. This parameter modification maintains cytolytic effectiveness while reducing inflammatory response, enabling more frequent treatments.
3Reliability
If high concentration of deoxycholic acid is used, then fat destruction is more effective, but inflammation and adverse effects increase
Solution Approach 1:
The gel creates local quality differences within the injection site, with high deoxycholic acid concentration confined to the gel core where it contacts fat cells directly, while surrounding tissues experience lower concentrations. This spatial differentiation maintains effective fat destruction at the target site while minimizing adverse effects in adjacent areas.
Solution Approach 2:
The gel matrix acts as an intermediary between deoxycholic acid and the surrounding tissue. It controls the interaction by limiting direct contact between high concentrations of the cytolytic agent and non-target tissues, thereby maintaining therapeutic effectiveness while reducing harmful side effects through controlled mediating release.
4Area of stationary object
If deoxycholic acid permeates deeply into fat tissue, then treatment coverage is extensive, but inflammation reaction spreads throughout the entire tissue area
Solution Approach 1:
The gel structure segments the treatment zone into a central high-concentration region and peripheral low-concentration regions. This segmentation confines the intense cytolytic action and associated inflammation to the gel core, while the periphery experiences milder effects, thus achieving localized treatment with limited inflammation spread.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces localized fat with minimized adverse effects such as inflammation and pain, allowing for fewer treatment sessions and a shorter overall treatment process.
Implementation Method 1
DCA-Na can form hydrogels under low pH, mixing with tris(hydroxymethyl)aminomethane (TRIS) buffer or mixing with polymers and an amino acid, L-aspartic acid
Implementation Method 2
When deoxycholate gel solution is injected into fat tissue, only fat cells surrounding deoxycholate gel are destroyed gradually during 7-days slow-releasing of deoxycholate
Data Source
AI summary
The present invention provides an injectable composition comprising cytolytic compound, preferably deoxycholic acid or a salt thereof, more preferably DCA-Na as a first component; and a pharmaceutically acceptable excipient. It also provides use of the injectable composition, for the reduction or removal of localized fat in a subject in need thereof, wherein the injectable composition is subcutaneously injected into a subcutaneous injection site of the subject. It also provides a method for reducing or removing localized fat in a subject in need thereof, comprising administering to the subject, an effective amount of the injectable composition. In particular, the injectable composition of the invention may be in the form of gel.